This study aimed to evaluate the performance of Cobas HPV test in cervical cancer screening. A total of 3,442 women aged ≥20 years used Cobas HPV and hybrid capture 2 (HC2) tests were included in this study. Women with any positive result were examined by liquid-based cytology (LBC) test. Then subjects with abnormal LBC or positive Cobas HPV16/18 were further checked up by colposcopy to observe the visible lesions to perform the pathological examination. Of these 3,442 women, 328 cases were Cobas HPV positive, and the positive rate was 9.53% [95% confidence intervals (CI), 8.50%-10.53%]. The positive rate of HPV16, HPV18, and other 12 types of high-risk HPV were 1.54% (95%CI, 1.12%-1.95%), 0.55% (95%CI, 0.30%-0.80%), and 7.44% (95%CI, 6.56%-8.32%), respectively. The coincidence rate of Cobas HPV test and HC2 test was 90% (95%CI, 89.00%-91.00%; Kappa = 0.526) in the primary screening. Age had a non-linear relationship with Cobas HPV positive rate (χ 2 = 4.240, P = 0.040) and HPV16/18 typing positive rate (χ 2 = 6.610, P = 0.010).Compared with the LBC test, the Cobas HPV test had higher sensitivity when detecting patients with high cervical intraepithelial neoplasia (CIN2+ and CIN3+).
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.